Tetrahedral framework nucleic acid carrying angiogenic peptide prevents bisphosphonate-related osteonecrosis of the jaw by promoting angiogenesis

Abstract

The significant clinical feature of bisphosphonate-related osteonecrosis of the jaw (BRONJ) is the exposure of the necrotic jaw. Other clinical manifestations include jaw pain, swelling, abscess, and skin fistula, which seriously affect the patients’ life, and there is no radical cure. Thus, new methods need to be found to prevent the occurrence of BRONJ. Here, a novel nanoparticle, tFNA-KLT, was successfully synthesized by us, in which the nanoparticle tetrahedral framework nucleic acid (tFNA) was used for carrying angiogenic peptide, KLT, and then further enhanced angiogenesis. TFNA-KLT possessed the same characteristics as tFNA, such as simple synthesis, stable structure, and good biocompatibility. Meanwhile, tFNA enhanced the stability of KLT and carried more KLT to interact with endothelial cells. First, it was confirmed that tFNA-KLT had the superior angiogenic ability to tFNA and KLT both in vitro and in vivo. Then we apply tFNA-KLT to the prevention of BRONJ. The results showed that tFNA-KLT can effectively prevent the occurrence of BRONJ by accelerating angiogenesis. In summary, the prepared novel nanoparticle, tFNA-KLT, was firstly synthesized by us. It was also firstly confirmed by us that tFNA-KLT significantly enhanced angiogenesis and can effectively prevent the occurrence of BRONJ by accelerating angiogenesis, thus providing a new avenue for the prevention of BRONJ and a new choice for therapeutic angiogenesis.

References

[1] Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J. Oral. Maxil. Surg., 2007, 65: 415-423.

[2] Singh M, Gonegandla GS. Bisphosphonate induced osteonecrosis of the jaws (BIONJ). J. Maxil. Oral. Surg., 2020, 19: 162-167.

[3] Falk W, . BRONJ- related jaw bone is associated with increased Dlx-5 and suppressed osteopontin—implication in the site-specific alteration of angiogenesis and bone turnover by bisphosphonates. Clin. Oral. Invest., 2015, 19: 1289-1298.

[4] Kilic, E. & Doganay, O. Current management concepts for bisphosphonate-related osteonecrosis of the jaw: a review. Gen. Dent. 66, e1–e5 (2018).

[5] Chang J, Hakam AE, Mccauley LK. Current understanding of the pathophysiology of osteonecrosis of the jaw. Curr. Osteoporos. Rep., 2018, 16: 584-595.

[6] Di Salvatore M, . Barone. Anti‐tumor and anti‐angiogenetic effects of zoledronic acid on human non‐small‐cell lung cancer cell line. Cell Proliferat., 2011, 44: 139-146.

[7] Loïc L, . Comparative study of neoadjuvant chemotherapy with and without Zometa for management of locally advanced breast cancer with serum VEGF as primary endpoint: the NEOZOL study. Clin. Breast Cancer, 2018, 18: e1311-e1321.

[8] Ferretti G, . Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology, 2005, 69: 35-43.

[9] James LB, . Correlation of changes in the mandible and retina/choroid vasculature of a rat model of BRONJ. J. Cranio-Maxill. Surg., 2015, 43: 1144-1150.

[10] Dan Z, . Tetrahedral framework nucleic acid promotes the treatment of bisphosphonate-related osteonecrosis of the jaws by promoting angiogenesis and M2 polarization. ACS Appl. Mater. Inter., 2020, 12: 44508-44522.

[11] Kuroshima S, Nakajima K, Sasaki M, Takashi I, Sawase T. Systemic administration of quality- and quantity-controlled pbmncs reduces bisphosphonate-related osteonecrosis of jaw-like lesions in mice. Stem Cell Res. Ther., 2019, 10: 209.

[12] Robert EM, Yoh S, Michel F, Vishtasb B. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J. Oral. Maxill. Surg., 2005, 63: 1567-1576.

[13] Fliefel R, Tröltzsch M, Kühnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int. J. Oral. Max. Surg., 2015, 44: 568-585.

[14] Matsumoto A, . Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab. Clin. Oral. Invest., 2017, 21: 1-8.

[15] Sao-Shen L, . Immediate hyperbaric oxygen after tooth extraction ameliorates bisphosphonate-related osteonecrotic lesion in rats. J. Periodontol., 2019, 90: 1449-1456.

[16] Voss PJ, . Treatment of stage ii medication-related osteonecrosis of the jaw with neurectomy and autologous bone marrow mesenchymal stem cells. Odontology, 2017, 105: 484-493.

[17] Cardoso CL, Curra C, Curi MM, Matsumoto MA, Jnior OF. Treatment of bisphosphonate-related osteonecrosis using platelet-rich plasma: microtomographic, microscopic, and immunohistochemical analyses. Braz. Oral. Res., 2019, 33: e050.

[18] Julie G. Angiogenesis in fracture repair. Clin. Orthop. Relat. R., 1998, 355: 82-89.

[19] Hu K, Olsen BR. The roles of vascular endothelial growth factor in bone repair and regeneration. Bone, 2016, 91: 30-38.

[20] D’Andrea L, . Targeting angiogenesis: structural characterization and biological properties of a de novo engineered VEGF mimicking peptide. Proc. Natl Acad. Sci. USA, 2005, 102: 14215-14220.

[21] Santulli G, . In vivo properties of the proangiogenic peptide QK. J. Trans. Med., 2009, 7: 41-50.

[22] Finetti F, Basile A, Capasso D, Gaetano SD, D’Andrea LD. Functional and pharmacological characterization of a VEGF mimetic peptide on reparative angiogenesis. Biochem. Pharmacol., 2012, 84: 303-311.

[23] Pensa NW, Curry AS, Reddy MS, Bellis SL. Sustained delivery of the angiogenic QK peptide through the use of polyglutamate domains to control peptide release from bone graft materials. J. Biomed. Mater. Res. A, 2019, 107: 2764-2773.

[24] Wenjuan, M. et al. Biomimetic nanoerythrosome-coated aptamer-DNA tetrahedron/maytansine conjugates: pH-responsive and targeted cytotoxicity for HER2-positive breast cancer. Adv. Mater. e2109609 (2022).

[25] Bowen, Z. et al. Facilitating in-situ tumor imaging with a tetrahedral DNA framework-enhanced hybridization chain reaction probe. Adv. Funct. Mater. 2109728 (2022).

[26] Mi Z, . A DNA nanostructure-based neuroprotectant against neuronal apoptosis via inhibiting toll-like receptor 2 signaling pathway in acute ischemic stroke. ACS Nano., 2022, 16: 1456-1470.

[27] Yuhao L, . Tetrahedral framework nucleic acids deliver antimicrobial peptides with improved effects and less susceptibility to bacterial degradation. Nano Lett., 2020, 20: 3602-3610.

[28] Mengting L, . Enhanced penetrability of a tetrahedral framework nucleic acid by modification with iRGD for DOX-targeted delivery to triple negative breast cancer. ACS Appl. Mater. Inter., 2021, 13: 25825-25835.

[29] Wood J, . Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J. Pharmacol. Exp. Ther., 2002, 302: 1055-1061.

[30] Pabst AM, Ziebart T, Ackermann M, Konerding MA, Walter C. Bisphosphonates’ antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D matrigel assay. Clin. Oral. Invest., 2014, 18: 1015-1022.

[31] Dan Z, . Tetrahedral DNA nanostructure promotes endothelial cell proliferation, migration, and angiogenesis via notch signaling pathway. ACS Appl. Mater. Inter., 2018, 10: 37911-37918.

[32] Shiyu L, . Antioxidative and angiogenesis-promoting effects of tetrahedral framework nucleic acids in diabetic wound healing with activation of the Akt/Nrf2/HO-1 pathway. ACS Appl. Mater. Inter., 2020, 12: 11397-11408.

[33] Dan Z, . Angiogenic aptamer-modified tetrahedral framework nucleic acid promotes angiogenesis in vitro and in vivo. ACS Appl. Mater. Inter., 2021, 13: 29439-29449.

[34] Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell, 2011, 146: 873-887.

[35] Tao Z, . Design, fabrication and applications of tetrahedral DNA nanostructure-based multifunctional complexes in drug delivery and biomedical treatment. Nat. Protoc., 2020, 15: 2728-2757.

[36] Tao, Z., Taoran, T. & Yunfeng, L. Functionalizing framework nucleic acid-based nanostructures for biomedical application. Adv. Mater. e2107820 (2021).

[37] Yun W, . Tetrahedral framework nucleic acids can alleviate taurocholate-induced severe acute pancreatitis and its subsequent multi-organ injury in mice. Nano Lett., 2022, 22: 1759-1768.

[38] Jun L, . Repair of infected bone defect with clindamycin-tetrahedral DNA nanostructure complex-loaded 3D bioprinted hybrid scaffold. Chem. Eng. J., 2022, 435: 134855.

[39] Mei Z, . Anti-inflammatory activity of curcumin-loaded tetrahedral framework nucleic acids on acute gouty. Arthritis Bioact. Mater., 2022, 8: 368-380.

[40] Xin Q, . Tetrahedral framework nucleic acids-based delivery of microRNA-155 inhibits choroidal neovascularization by regulating the polarization of macrophages. Bioact. Mater., 2022, 14: 134-144.

[41] Silva ML, . Effect of hyperbaric oxygen therapy on tooth extraction sites in rats subjected to bisphosphonate therapy—histomorphometric and immunohistochemical analysis. Clin. Oral. Invest., 2017, 21: 199-210.

[42] Rupel K, . A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral. Oncol., 2014, 50: 1049-1057.

[43] Rodolfo M, . Conservative surgical treatment of bisphosphonate-related osteonecrosis of the jaw with Er,Cr:YSGG laser and platelet-rich plasma: a longitudinal study. Biomed. Res. Int., 2018, 2018: 1-10.

[44] Martins MAT, . Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study. Oral. Oncol., 2012, 48: 79-84.

[45] Longo F, . Platelet rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw: personal experience and review of the literature. Inter. J. Dent., 2014, 2014: 1-7.

[46] Maluf, G., Caldas, R. J., Fregnani, E. R. & Santos, P. A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants. Inter. J. Implant Dent. 5, 1–6 (2019).

[47] Mohamed HAM, Nielsen CEN, Schiodt M. Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. a report of 7 cases from the Copenhagen cohort. Oral Surg. Oral Med. Oral Pathol. Oral Radiol., 2017, 125: 157-163.

[48] Xiaoyuan J, . Protein-mimicking nanoparticles for a cellular regulation of homeostasis. ACS Appl. Mater. inter,, 2021, 13: 31331-31336.

[49] Yanfeng Z, . An organelle‐specific nanozyme for diabetes care in genetically or diet‐induced models. Adv. Mater.,, 2020, 32: 2003708.

Funding

National Science Foundation of China | National Natural Science Foundation of China-Yunnan Joint Fund (NSFC-Yunnan Joint Fund)(81970916, 81870746)